SPRAY-DRIED solid inhalable N-acetylcysteine microparticles: Preparation and mucolytic activity testing

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216305%3A26210%2F26%3A0200136" target="_blank" >RIV/00216305:26210/26:0200136 - isvavai.cz</a>

Výsledek na webu

<a href="https://www.sciencedirect.com/science/article/pii/S1773224725010251?pes=vor&utm_source=clarivate&getft_integrator=clarivate" target="_blank" >https://www.sciencedirect.com/science/article/pii/S1773224725010251?pes=vor&utm_source=clarivate&getft_integrator=clarivate</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.jddst.2025.107622" target="_blank" >10.1016/j.jddst.2025.107622</a>

Jazyk výsledku

angličtina

Název v původním jazyce

SPRAY-DRIED solid inhalable N-acetylcysteine microparticles: Preparation and mucolytic activity testing

Popis výsledku v původním jazyce

Inhalation is the preferred administration for treating pulmonary disorders like cystic fibrosis, with the use of mucolytics such as N-acetylcysteine being the main therapeutic strategy. This study aimed to develop spray-dried inhalable microparticles, using N-acetylcysteine and mannitol as a carrier and osmotic agent. Various methodologies were assessed to optimize the spray drying process, including different drying conditions and additives in the dispersion. The results demonstrated the requirements for particular excipients to formulate N-acetylcysteine-mannitol inhalable microparticles by spray drying. Incorporating a neutralizing agent (sodium hydroxide) or glass transition temperature modifiers (dextran, maltodextrin, chitosan) produced spherical primary particles that readily agglomerated into large clusters. Leucine, as an antiadherent agent, demonstrated efficacy as the sole excipient at a concentration of 20-25 %, facilitating the formulation of particles with appropriate size, shape, and morphology. Inhalable particles (mass median aerodynamic diameter 5.95 +/- 1.53 mu m, fine particle fraction 33.06 %) were prepared by modifying process parameters (nozzle size reduction, feed solution dilution). The encapsulated N-acetylcysteine also showed sustained mucolytic activity in vitro (35.3 % viscosity reduction after 120 min), using an innovative method. This work represents the complex study of N-acetylcysteine inhalable microparticles preparation as a possible approach to overcome liquid formulation.

Název v anglickém jazyce

SPRAY-DRIED solid inhalable N-acetylcysteine microparticles: Preparation and mucolytic activity testing

Popis výsledku anglicky

Inhalation is the preferred administration for treating pulmonary disorders like cystic fibrosis, with the use of mucolytics such as N-acetylcysteine being the main therapeutic strategy. This study aimed to develop spray-dried inhalable microparticles, using N-acetylcysteine and mannitol as a carrier and osmotic agent. Various methodologies were assessed to optimize the spray drying process, including different drying conditions and additives in the dispersion. The results demonstrated the requirements for particular excipients to formulate N-acetylcysteine-mannitol inhalable microparticles by spray drying. Incorporating a neutralizing agent (sodium hydroxide) or glass transition temperature modifiers (dextran, maltodextrin, chitosan) produced spherical primary particles that readily agglomerated into large clusters. Leucine, as an antiadherent agent, demonstrated efficacy as the sole excipient at a concentration of 20-25 %, facilitating the formulation of particles with appropriate size, shape, and morphology. Inhalable particles (mass median aerodynamic diameter 5.95 +/- 1.53 mu m, fine particle fraction 33.06 %) were prepared by modifying process parameters (nozzle size reduction, feed solution dilution). The encapsulated N-acetylcysteine also showed sustained mucolytic activity in vitro (35.3 % viscosity reduction after 120 min), using an innovative method. This work represents the complex study of N-acetylcysteine inhalable microparticles preparation as a possible approach to overcome liquid formulation.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30104 - Pharmacology and pharmacy

Projekt

<a href="/cs/project/GA25-16971S" target="_blank" >GA25-16971S: Vliv změn geometrie dýchacích cest a dechového režimu při astmatu na proudění a usazování částic</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2025

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Journal of drug delivery science and technology

ISSN

—

e-ISSN

2588-8943

Svazek periodika

—

Číslo periodika v rámci svazku

114

Stát vydavatele periodika

NL - Nizozemsko

Počet stran výsledku

14

Strana od-do

—

Kód UT WoS článku

001594167000001

EID výsledku v databázi Scopus

2-s2.0-105018769263